Skip to main content


You are here

Gliknik Expands Clinical Development Team with New Senior Director and Adds Board Members

Wednesday, February 19, 2014

- Jeffrey Herpst joins Baltimore-based Gliknik Inc. to advance mid-stage clinical drug candidates in Gliknik's innovative immunomodulator program -

- Mark Lerner and Richard Levy elected to Gliknik Board of Directors –

BALTIMORE, Feb. 19, 2014 /PRNewswire/ -- Gliknik Inc., a privately held biopharmaceutical company, today announced that it has expanded its team by adding a new Senior Director of Clinical Development and electing two new members to its Board of Directors. Gliknik is deepening its clinical staff and allocating resources to further advance GL-0817 and GL-0810, two cancer therapeutic vaccines. These clinical-stage vaccine candidates are designed to fight specific cancers by augmenting the body's immune response to tumors.

Jeffrey Herpst, R.N., joins Gliknik as Senior Director, Clinical Development. Mr. Herpst has 20 years' experience in clinical operations and has held clinical development roles of increasing responsibility, most recently at Zyngenia, Teva, and Human Genome Sciences. Before entering industry, Mr. Herpst was a Research Nurse for seven years at Johns Hopkins in the Division of Radiation Oncology.

Read the full Gliknik press release